Social media defined as "a conversation supported by online tools," is transforming the way people communicate across the globe. Basically, social media consists of online applications that allow users to generate content, connect with others, and engage in conversation. Many social media sites exist, but healthcare professionals may not know that social media also exists in their realm. It ranges from online medical advice to actual patient-physician appointments. It includes educational banks, public health information dissemination, and online data-platform sharing. Patients use healthcare social media for peer support and empowerment through patient-centered websites.
Web 2.0 is a philosophy associated with online applications that facilitates interactive information sharing, collaboration, while being user-centered. Web 2.0 was adopted by healthcare participants to utilize the core concepts of openness, social networking, participation, collaboration, and apomediation. Apomediation refers to cutting out any middlemen or "gatekeepers" when accessing Internet information and going directly to the information, which is vetted by experts.
"One major concern of healthcare professionals regarding the use of social media in healthcare is that, by nature, it is open and the information is not ‘controllable,’” according to Jeff Cain, EdD, MS, director of education technology at the University of Kentucky College of Pharmacy, Lexington, Ky., who spoke on this topic at the 22nd annual meeting of the Academy of Managed Care Pharmacy in San Diego.
"Many healthcare professionals also use micro-blogging applications such as Twitter to disseminate and receive health-related information and research. By following other healthcare Twitterers, one can quickly be introduced to new publications, stories, and online articles of interest that she or he may not have discovered without extensive searching," said Dr Cain.
Examples of healthcare community sharing sites are PatientsLikeMe, HelloHealth, and Google Health. PatientsLikeMe is a site for patients with similar disease states. Currently there are more than 60,000 users for 19 conditions. Patients communicate about treatments, side effects, and other topics. Patient information is de-identified and aggregated, and can be purchased by pharmaceutical companies and health plans, to be used for research and marketing purposes.
“From the patient perspective, social media has permitted the unprecedented ability for users to socially connect with others who suffer from the same affliction or disease state,” according to Dr Cain. “For those with rare diseases, social networking capabilities of some of the patient community sites allow patients to locate, communicate with, encourage, and support others with similar problems.”
Social networking helpful for patients, but may need to be vetted
Many social media sites exist, but healthcare professionals may not know that social media also exists in their realm. It ranges from online medical advice to actual patient-physician appointments.
Social media defined as "a conversation supported by online tools," is transforming the way people communicate across the globe. Basically, social media consists of online applications that allow users to generate content, connect with others, and engage in conversation. Many social media sites exist, but healthcare professionals may not know that social media also exists in their realm. It ranges from online medical advice to actual patient-physician appointments. It includes educational banks, public health information dissemination, and online data-platform sharing. Patients use healthcare social media for peer support and empowerment through patient-centered websites.
Web 2.0 is a philosophy associated with online applications that facilitates interactive information sharing, collaboration, while being user-centered. Web 2.0 was adopted by healthcare participants to utilize the core concepts of openness, social networking, participation, collaboration, and apomediation. Apomediation refers to cutting out any middlemen or "gatekeepers" when accessing Internet information and going directly to the information, which is vetted by experts.
"One major concern of healthcare professionals regarding the use of social media in healthcare is that, by nature, it is open and the information is not ‘controllable,’” according to Jeff Cain, EdD, MS, director of education technology at the University of Kentucky College of Pharmacy, Lexington, Ky., who spoke on this topic at the 22nd annual meeting of the Academy of Managed Care Pharmacy in San Diego.
"Many healthcare professionals also use micro-blogging applications such as Twitter to disseminate and receive health-related information and research. By following other healthcare Twitterers, one can quickly be introduced to new publications, stories, and online articles of interest that she or he may not have discovered without extensive searching," said Dr Cain.
Examples of healthcare community sharing sites are PatientsLikeMe, HelloHealth, and Google Health. PatientsLikeMe is a site for patients with similar disease states. Currently there are more than 60,000 users for 19 conditions. Patients communicate about treatments, side effects, and other topics. Patient information is de-identified and aggregated, and can be purchased by pharmaceutical companies and health plans, to be used for research and marketing purposes.
“From the patient perspective, social media has permitted the unprecedented ability for users to socially connect with others who suffer from the same affliction or disease state,” according to Dr Cain. “For those with rare diseases, social networking capabilities of some of the patient community sites allow patients to locate, communicate with, encourage, and support others with similar problems.”
FDA Approves New Pompe Therapy
FDA Sets Review Date for Odronextamab to Treat Blood Cancers
Analysis: Farxiga is a High-Value Medication for Patients with Heart Failure
Cross-Contamination Leads to Recall of Two Lots of Brexafemme
FDA Approves Extended-Release Therapy for Major Depression
FDA Grants Priority Review for Sotatercept in Pulmonary Arterial Hypertension
FDA Approves New Pompe Therapy
FDA Sets Review Date for Odronextamab to Treat Blood Cancers
Analysis: Farxiga is a High-Value Medication for Patients with Heart Failure
Cross-Contamination Leads to Recall of Two Lots of Brexafemme
FDA Approves Extended-Release Therapy for Major Depression
FDA Grants Priority Review for Sotatercept in Pulmonary Arterial Hypertension
FDA Approves New Pompe Therapy
FDA Sets Review Date for Odronextamab to Treat Blood Cancers
Analysis: Farxiga is a High-Value Medication for Patients with Heart Failure
Cross-Contamination Leads to Recall of Two Lots of Brexafemme
FDA Approves Extended-Release Therapy for Major Depression
FDA Grants Priority Review for Sotatercept in Pulmonary Arterial Hypertension
FDA Approves New Pompe Therapy
September 29th 2023The two-component therapy of Pombiliti plus Opfolda to treat adults living with late-onset Pompe disease will have an annual list price of $650,000.
FDA Sets Review Date for Odronextamab to Treat Blood Cancers
September 29th 2023Odronextamab is a bispecific antibody to treat relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma. The target action date is March 31, 2024.
Analysis: Farxiga is a High-Value Medication for Patients with Heart Failure
September 29th 2023The recent study also found that Jardiance for patients with heart failure with preserved ejection fraction could be cost-effective if discounted by 29%.
Cross-Contamination Leads to Recall of Two Lots of Brexafemme
September 28th 2023Contamination of Brexafemme with a non-antibacterial beta-lactam drug could lead to reactions such as swelling, rash, urticaria and anaphylaxis.
FDA Approves Extended-Release Therapy for Major Depression
September 28th 2023Exxua is approved to treat adults with major depressive disorder, but its labeling does not contain warnings about sexual function or weight gain.
FDA Grants Priority Review for Sotatercept in Pulmonary Arterial Hypertension
September 28th 2023Sotatercept is a first-in-class therapy to treat the rare disease pulmonary arterial hypertension. The FDA has assigned a target action date of March 26, 2024.